Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VTP-300 Combined With Low-dose Nivolumab in Chronic Hepatitis B Infection
NCT05343481Phase 2Completed
- Sponsor
- Barinthus Biotherapeutics
- Start
- Sep 2022
- Primary completion
- Jan 2026
- Modality
- Prophylactic Vaccines, Viral Vectors, DNA Vaccines
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of ChAdOx1-HBV and MVA-HBV in Chronic Hepatitis B (CHB) (3 arms), sponsored by Barinthus Biotherapeutics. Primary endpoint: Incidence of participants with a greater than 1 log HBsAg reduction at 6 months. Started Sep 2022; status: completed.
02
Drugs
ChAdOx1-HBVMVA-HBV
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05343481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05343481.